Advertisement
UK markets closed
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • FTSE 250

    19,884.73
    +74.07 (+0.37%)
     
  • AIM

    743.26
    +1.15 (+0.15%)
     
  • GBP/EUR

    1.1708
    +0.0014 (+0.12%)
     
  • GBP/USD

    1.2640
    +0.0017 (+0.14%)
     
  • Bitcoin GBP

    55,454.75
    -917.97 (-1.63%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • CAC 40

    8,205.81
    +1.00 (+0.01%)
     

Cells from centre of tumours most likely to spread around body – study

Cells from different parts of kidney tumours behave differently and those within the centre are the most aggressive and have the highest chance of spreading around the body, a new study has found.

Cancers can spread to other parts of the body, with cells taking hold as secondary tumours, making the disease much harder to treat.

Understanding the mechanics of this spread, a process called metastasis, could lead to new treatments that block this migration.

Scientists led by the Litchfield lab at UCL and the Turajlic, Swanton, and Bates labs at the the Francis Crick Institute analysed 756 cancer biopsy samples from different regions within tumours from the TRACERx Renal study.

ADVERTISEMENT

They found that cells at the centre of tumours have a less stable genome and a higher potential to spread to secondary sites around the body.

Samra Turajlic, head of the Crick’s Cancer Dynamics Laboratory, consultant medical oncologist at the Royal Marsden NHS Foundation Trust and chief investigator of TRACERx Renal, said: “Using this unique clinical cohort and a multidisciplinary approach, including mathematical modelling, we identified with precision the place in the tumour where genetic chaos emerges to give rise to metastases.

“Our observations shed light on the sort of environmental conditions that would foster emergence of aggressive behaviour.

“These findings are a critical foundation for considering how we target or even prevent distinct populations of cells that pose the biggest threat.”

Cells at the tumour edge had lower rates of metastasis, as well as lower rates of growth and genetic damage, according to the study published in Nature Ecology and Evolution.

Kevin Litchfield, paper author and group leader at the UCL Cancer Institute, said: “Cancer cells in the central zone of the tumour face harsh environmental conditions, as there’s a lack of blood supply and oxygen.

“They have to adapt to survive, which makes them stronger and more aggressive.

“This also means they are more likely to successfully evolve into cells that can disseminate and take hold in distant organs.”

The researchers say their findings highlight a need to pay close attention to the tumour centre to understand how cancer spreads and to find the cancer cells of greatest threat to the patient.

It further indicates the importance of developing treatments that target the unique environmental conditions found within the tumour core, in order to successfully eliminate the most aggressive tumour cells.

The scientists also looked at how genetically different populations of cancer cells grow within a tumour.

Using a unique map-building tool to reconstruct the growth of tumour cells, they found that while most tumours follow a pattern where populations of cells grow in the local area – like a plant growing up and outwards – two cases demonstrated a jumping pattern where cells took hold in a new region of the tumour by seemingly jumping over other populations of tumour cells .

The researchers are now planning to reconstruct 3D tumour maps, which will provide an even clearer visualisation of the spatial patterns within tumours.

The work was primarily funded by the Royal Marsden Renal Unit, the Biomedical Research Centre at the Royal Marsden and Institute of Cancer Research, Cancer Research UK, Rosetrees Trust, the National Institute for Health Research (NIHR) and the EU Framework Programme for Research and Innovation H2020.